MXPA03003704A - Formulacion de kahalalide f. - Google Patents
Formulacion de kahalalide f.Info
- Publication number
- MXPA03003704A MXPA03003704A MXPA03003704A MXPA03003704A MXPA03003704A MX PA03003704 A MXPA03003704 A MX PA03003704A MX PA03003704 A MXPA03003704 A MX PA03003704A MX PA03003704 A MXPA03003704 A MX PA03003704A MX PA03003704 A MXPA03003704 A MX PA03003704A
- Authority
- MX
- Mexico
- Prior art keywords
- kahalalide
- formulation
- new
- formulations
- new uses
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RCGXNDQKCXNWLO-GZEKAAEYSA-N kahalalide f Chemical compound CC1OC(=O)C(C(C)C)NC(=O)\C(=C\C)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C1NC(=O)C(C(C)CC)NC(=O)C(CCCN)NC(=O)C1CCCN1C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCCC(C)C)C(C)C)C(C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-GZEKAAEYSA-N 0.000 title 1
- RCGXNDQKCXNWLO-WLEIXIPESA-N (2r)-n-[(2s)-5-amino-1-[[(2r,3r)-1-[[(3s,6z,9s,12r,15r,18r,19s)-9-benzyl-15-[(2r)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@H]1C)C(C)C)=C\C)C(C)C)[C@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-WLEIXIPESA-N 0.000 abstract 1
- 108010091711 kahalalide F Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24447100P | 2000-10-31 | 2000-10-31 | |
| US24622900P | 2000-11-06 | 2000-11-06 | |
| US34844901P | 2001-10-19 | 2001-10-19 | |
| PCT/GB2001/004821 WO2002036145A2 (en) | 2000-10-31 | 2001-10-31 | Kahalalide f formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03003704A true MXPA03003704A (es) | 2004-05-04 |
Family
ID=27399760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03003704A MXPA03003704A (es) | 2000-10-31 | 2001-10-31 | Formulacion de kahalalide f. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7473681B2 (https=) |
| EP (1) | EP1330258B1 (https=) |
| JP (2) | JP2004512370A (https=) |
| KR (1) | KR100834138B1 (https=) |
| CN (1) | CN1568192A (https=) |
| AT (1) | ATE314084T1 (https=) |
| AU (2) | AU1074902A (https=) |
| BR (1) | BR0114912A (https=) |
| CA (1) | CA2425627A1 (https=) |
| CY (1) | CY1105009T1 (https=) |
| CZ (1) | CZ20031211A3 (https=) |
| DE (1) | DE60116359T2 (https=) |
| DK (1) | DK1330258T3 (https=) |
| ES (1) | ES2256305T3 (https=) |
| HK (1) | HK1054192B (https=) |
| HU (1) | HUP0600031A3 (https=) |
| IL (2) | IL155297A0 (https=) |
| MX (1) | MXPA03003704A (https=) |
| NO (1) | NO331082B1 (https=) |
| NZ (1) | NZ525243A (https=) |
| SK (1) | SK286421B6 (https=) |
| WO (1) | WO2002036145A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| US20050054555A1 (en) * | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
| WO2003033012A1 (en) * | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Kahalalide compounds for use in cancer therapy |
| GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
| DK1572726T3 (da) * | 2002-10-18 | 2011-03-28 | Pharma Mar Sau | 4-methylhexansyre-kahalalid F-forbindelse |
| NZ539093A (en) * | 2002-10-18 | 2007-10-26 | Pharma Mar Sau | 4-methylhexanoic kahalaide F compound |
| US7507708B2 (en) | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
| DE10329847A1 (de) * | 2003-07-02 | 2005-01-20 | Toximed Gmbh | Pharmazeutischer Wirkstoff gegen Prostatakarzinome |
| GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
| GB0408958D0 (en) * | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
| DK1827500T3 (da) * | 2004-10-26 | 2009-08-31 | Pharma Mar Sa | Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743 |
| RS50510B (sr) | 2004-10-29 | 2010-03-02 | Pharma Mar S.A., Sociedad Unipersonal | Formulacije koje sadrže ekteinascidin i disaharid |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| WO2009052379A2 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Improved antitumoral treatments |
| AU2009209541A1 (en) * | 2008-01-30 | 2009-08-06 | Pharma Mar, S.A. | Improved antitumoral treatments |
| CN101965192A (zh) * | 2008-03-07 | 2011-02-02 | 法马马有限公司 | 改善的抗肿瘤治疗 |
| WO2009135939A2 (en) * | 2008-05-09 | 2009-11-12 | Pharma Mar, S.A. | Depsipeptide for use in cancer therapy |
| HRP20231233T1 (hr) | 2017-04-27 | 2024-01-19 | Pharma Mar, S.A. | Antitumorski spojevi |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
| JP2799483B2 (ja) | 1988-03-09 | 1998-09-17 | 大塚製薬株式会社 | インターロイキン−１β組成物の安定化方法 |
| GB8819607D0 (en) | 1988-08-17 | 1988-09-21 | Wellcome Found | Novel combination |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| JP2971680B2 (ja) | 1991-10-02 | 1999-11-08 | 山之内製薬株式会社 | 組織プラスミノーゲン活性化因子含有組成物 |
| JPH0597703A (ja) | 1991-10-04 | 1993-04-20 | Yamanouchi Pharmaceut Co Ltd | 改変型組織プラスミノーゲン活性化因子含有組成物 |
| US5550124A (en) | 1991-12-10 | 1996-08-27 | University Of Southern California | Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease |
| US5849704A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| GB9302046D0 (en) * | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Antiumoral compound-v |
| US6274551B1 (en) * | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
| JP3927248B2 (ja) * | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Ｈｇｆ凍結乾燥製剤 |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| JPH1014581A (ja) | 1996-07-08 | 1998-01-20 | Morinaga Milk Ind Co Ltd | ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片 |
| DE69719265T2 (de) | 1996-09-06 | 2003-12-04 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto | Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält |
| JP4025394B2 (ja) * | 1996-09-06 | 2007-12-19 | 財団法人化学及血清療法研究所 | 組織プラスミノーゲン活性化因子医薬組成物 |
| GB9803448D0 (en) * | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| GB9807639D0 (en) | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| CN1322136A (zh) | 1998-09-23 | 2001-11-14 | 马库斯·基普 | 用于选择性神经元辐射防护的神经亲免素类物质 |
| GB0002952D0 (en) | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| US20050054555A1 (en) | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
-
2001
- 2001-10-31 ES ES01978654T patent/ES2256305T3/es not_active Expired - Lifetime
- 2001-10-31 SK SK502-2003A patent/SK286421B6/sk not_active IP Right Cessation
- 2001-10-31 JP JP2002538956A patent/JP2004512370A/ja active Pending
- 2001-10-31 EP EP01978654A patent/EP1330258B1/en not_active Expired - Lifetime
- 2001-10-31 AU AU1074902A patent/AU1074902A/xx active Pending
- 2001-10-31 BR BR0114912-1A patent/BR0114912A/pt active Search and Examination
- 2001-10-31 CA CA002425627A patent/CA2425627A1/en not_active Abandoned
- 2001-10-31 AT AT01978654T patent/ATE314084T1/de active
- 2001-10-31 HK HK03106441.9A patent/HK1054192B/en not_active IP Right Cessation
- 2001-10-31 DE DE60116359T patent/DE60116359T2/de not_active Expired - Lifetime
- 2001-10-31 MX MXPA03003704A patent/MXPA03003704A/es active IP Right Grant
- 2001-10-31 AU AU2002210749A patent/AU2002210749B2/en not_active Ceased
- 2001-10-31 DK DK01978654T patent/DK1330258T3/da active
- 2001-10-31 CN CNA018182712A patent/CN1568192A/zh active Pending
- 2001-10-31 NZ NZ525243A patent/NZ525243A/en unknown
- 2001-10-31 KR KR1020037005347A patent/KR100834138B1/ko not_active Expired - Fee Related
- 2001-10-31 WO PCT/GB2001/004821 patent/WO2002036145A2/en not_active Ceased
- 2001-10-31 HU HU0600031A patent/HUP0600031A3/hu unknown
- 2001-10-31 US US10/399,571 patent/US7473681B2/en not_active Expired - Fee Related
- 2001-10-31 IL IL15529701A patent/IL155297A0/xx unknown
- 2001-10-31 CZ CZ20031211A patent/CZ20031211A3/cs unknown
-
2003
- 2003-04-08 IL IL155297A patent/IL155297A/en not_active IP Right Cessation
- 2003-04-25 NO NO20031860A patent/NO331082B1/no not_active IP Right Cessation
-
2006
- 2006-03-24 CY CY20061100415T patent/CY1105009T1/el unknown
-
2009
- 2009-10-23 JP JP2009244772A patent/JP2010047601A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003704A (es) | Formulacion de kahalalide f. | |
| MXPA03005769A (es) | Politrimetilen eter ester amida y uso de la misma. | |
| AU144678S (en) | Bottle | |
| MX265024B (es) | Formulaciones de glifosato de potasio. | |
| IL140710A0 (en) | Pulmonary delivery of active agents | |
| NO20004540L (no) | Sammensetninger av peptider, formuleringer og anvendelse derav | |
| IL147803A0 (en) | 28-epirapalogs | |
| AU2001247486A1 (en) | Hair restoration formulation | |
| AU5002301A (en) | Cosmetic compositions comprising exfoliating enzymes and uses thereof | |
| AU5186799A (en) | Peptides of il-2 and derivatives thereof and their use as therapeutic agents | |
| AU2001272615A1 (en) | Amphipathic linear peptides and compositions containing same | |
| AU2002218195A1 (en) | Silicone rubber formulations and the use thereof | |
| MY133881A (en) | "calcilytic compounds" | |
| AP2002002547A0 (en) | Calcilytic compounds. | |
| EP1383511A4 (en) | CALCILYTIC COMPOUNDS | |
| WO2002077233A8 (en) | 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF | |
| AU7655600A (en) | 1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one | |
| AU2001271281A1 (en) | Novel compositions for the expression of the human peptide histidine transporter1 and methods of use thereof | |
| AUPQ760400A0 (en) | Herbical formulations and methods of use thereof | |
| AU2001247214A1 (en) | Hair treatment compositions and their use | |
| AU2001296780A1 (en) | 48120, 23479, and 46689, novel human hydrolases and uses thereof | |
| AUPQ599500A0 (en) | Novel peptides, modulatory agents therefor and methods of using them | |
| AU2001297794A1 (en) | Methods and compositions of human proteins and uses thereof. | |
| IL143644A0 (en) | Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents | |
| AU2001239815A1 (en) | Hair treatment compositions and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |